Advances of nanoscale science have produced nanomaterials with unique physical and chemical properties at commercial levels which are now incorporated into over 1000 products. Nanoscale cerium (di) oxide (CeO(2)) has recently gained a wide range of applications which includes coatings, electronics, biomedical, energy and fuel additives. Many applications of engineered CeO(2) nanoparticles are dispersive in nature increasing the risk of exposure and interactions with a variety of environmental media with unknown health, safety and environmental implications. As evident from a risk assessment perspective, the health effects of CeO(2) nanoparticles are not only dependent on their intrinsic toxicity but also on the level of exposure to these novel materials. Although this may seem logical, numerous studies have assessed the health effects of nanoparticles without this simple but critical risk assessment perspective. This review extends previous exposure and toxicological assessments for CeO(2) particles by summarizing the current state of micro and nano-scale cerium exposure and health risks derived from epidemiology, air quality monitoring, fuel combustion and toxicological studies to serve as a contemporary comprehensive and integrated toxicological assessment. Based on the new information presented in this review there is an ongoing exposure to a large population to new diesel emissions generated using fuel additives containing CeO2 nanoparticles for which the environmental (air quality and climate change) and public health impacts of this new technology are not known. Therefore, there is an absolute critical need for integrated exposure and toxicological studies in order to accurately assess the environmental, ecological and health implications of nanotechnology enabled diesel fuel additives with existing as well as new engine designs and fuel formulations.

No abstract

The relative importance of the three particulate matter (PM) size fractions in ambient air, i.e. coarse (2.5-10 microm), fine (0.1-2.5 microm) and ultrafine (<0.1 microm) fractions, on the induction of adverse health effects is still unknown. Moreover, there is no straightforward relationship between ambient concentration levels, exposure (external dose) and the dose delivered to the target site (internal dose). Recently, a human and a rat airway PM deposition model (MPPDep V1.1) have been developed by CIIT Centers for Health Research and the National Institute of Public Health and the Environment (RIVM), based on the work of O.G. Raabe et al. (1977, In: W.H. Walton, editor, Inhaled Particles IV/2; Pergamon, Oxford) and S. Anjilvel and B. Asgharian (1995, Fundam Appl Toxicol 28:41-50). This paper describes studies using cadmium chloride (CdCl(2)) as a model for toxic aerosol particles to (1) investigate the role of particle size in the development of pulmonary effects, and (2) evaluate the MPPDep model, by comparing predicted deposition with measured deposition of CdCl(2)in the respiratory tract. Rats (ten per group) were exposed for a single 4-h period to CdCl(2)particles at various sizes, i.e. 33, 170, 637 and 1495 nm, all at a target concentration of 1 mg/m(3). Immediately after exposure, four of ten rats per group were killed and trachea, lung lobes, heart, liver and kidneys were collected and preserved to determine the amount of CdCl(2) present in each of these organs. CdCl(2)-induced toxicity, as measured by lactate dehydrogenase (LDH), N-acetyl glucosaminidase (NAG) and protein levels in bronchoalveolar lavage fluid, was determined in the remaining six rats per group the day after exposure. Animals exposed to 33 nm particles showed the highest level of respiratory toxicity, followed by animals exposed to 637 nm particles, then to 170 nm particles and finally by those exposed to 1495 nm particles. Pulmonary cadmium levels showed a similar relationship. The results from the present study suggest that the induction of pulmonary toxicity following inhalation exposure to soluble CdCl(2)particles in the range 30-1500 nm depends on the amount of deposited material, which in its turn depends on the initial (aerodynamic) particle size. In addition, the MPPDep model accurately predicted the measured CdCl(2) deposition. Conclusively, for soluble particles the deposited pulmonary mass (dose) of particles is important for toxicity and is dependent of particle size. These findings may have serious impact on the evaluation of the role of various particle sizes in PM10-associated health effects.

There are many uncertainties regarding the hazard of nanosized particles compared to the bulk material of the parent chemical. Here, the authors assess the comparative hazard of two nanoscale (NM-211 and NM-212) and one microscale (NM-213) cerium oxide materials in 28-day inhalation toxicity studies in rats (according to Organisation for Economic Co-operation and Development technical guidelines). All three materials gave rise to a dose-dependent pulmonary inflammation and lung cell damage but without gross pathological changes immediately after exposure. Following NM-211 and NM-212 exposure, epithelial cell injury was observed in the recovery groups. There was no evidence of systemic inflammation or other haematological changes following exposure of any of the three particle types. The comparative hazard was quantified by application of the benchmark concentration approach. The relative toxicity was explored in terms of three exposure metrics. When exposure levels were expressed as mass concentration, nanosized NM-211 was the most potent material, whereas when expression levels were based on surface area concentration, micro-sized NM-213 material induced the greatest extent of pulmonary inflammation/damage. Particles were equipotent based on particle number concentrations. In conclusion, similar pulmonary toxicity profiles including inflammation are observed for all three materials with little quantitative differences. Systemic effects were virtually absent. There is little evidence for a dominant predicting exposure metric for the observed effects.

No abstract